Synapse

← Journal of Market Access & Health Policy

Papers in Journal of Market Access & Health Policy

Page 6 · newest first

  1. A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reportingJournal of Market Access & Health Policy · 2017
  2. Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industryJournal of Market Access & Health Policy · 2017
  3. Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndromeJournal of Market Access & Health Policy · 2017
  4. A comparative study of orphan drug prices in EuropeJournal of Market Access & Health Policy · 2017
  5. Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in ItalyJournal of Market Access & Health Policy · 2017
  6. Value added medicines: what value repurposed medicines might bring to society?Journal of Market Access & Health Policy · 2016
  7. Advanced therapy medicinal products: current and future perspectivesJournal of Market Access & Health Policy · 2016
  8. Determining the value of medical technologies to treat ultra-rare disorders: a consensus statementJournal of Market Access & Health Policy · 2016
  9. A training paradigm to enhance performance and safe use of an innovative neuroendovascular deviceJournal of Market Access & Health Policy · 2016
  10. Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populationsJournal of Market Access & Health Policy · 2016
  11. Drug pricing reform in China: analysis of piloted approaches and potential impact of the reformJournal of Market Access & Health Policy · 2016
  12. The value of innovation under value-based pricingJournal of Market Access & Health Policy · 2016
  13. Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settingsJournal of Market Access & Health Policy · 2016
  14. Feasibility and attractiveness of indication value-based pricing in key EU countriesJournal of Market Access & Health Policy · 2016
  15. The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5DJournal of Market Access & Health Policy · 2016
  16. Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profilesJournal of Market Access & Health Policy · 2016
  17. The Economic Value of Vaccination: Why Prevention is WealthJournal of Market Access & Health Policy · 2015
  18. Vaccination: the cornerstone of an efficient healthcare systemJournal of Market Access & Health Policy · 2015
  19. Market access pathways for cell therapies in FranceJournal of Market Access & Health Policy · 2015
  20. Reimbursement of licensed cell and gene therapies across the major European healthcare marketsJournal of Market Access & Health Policy · 2015
  21. Role of vaccination in the sustainability of healthcare systemsJournal of Market Access & Health Policy · 2015
  22. Role of vaccination in economic growthJournal of Market Access & Health Policy · 2015
  23. Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopramJournal of Market Access & Health Policy · 2015
  24. Ischemic stroke management in West Scotland: a chart reviewJournal of Market Access & Health Policy · 2015
  25. A review of accessibility of administrative healthcare databases in the Asia-Pacific regionJournal of Market Access & Health Policy · 2015
  26. Overview of external reference pricing systems in EuropeJournal of Market Access & Health Policy · 2015
  27. A chart review of management of ischemic stroke patients in GermanyJournal of Market Access & Health Policy · 2015
  28. From population to public institutions: what needs to be changed to benefit from the full value of vaccinationJournal of Market Access & Health Policy · 2015
  29. The economic value of vaccination: why prevention is wealthJournal of Market Access & Health Policy · 2015
  30. A review of the value of innovation in inhalers for COPD and asthmaJournal of Market Access & Health Policy · 2015
  31. The societal role of lifelong vaccinationJournal of Market Access & Health Policy · 2015
  32. National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learningJournal of Market Access & Health Policy · 2015
  33. A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environmentsJournal of Market Access & Health Policy · 2015
  34. Is the gap between micro- and macroeconomic assessments in health care well understood? The case of vaccination and potential remediesJournal of Market Access & Health Policy · 2014
  35. Are payers treating orphan drugs differently?Journal of Market Access & Health Policy · 2014
  36. The value of quantitative patient preferences in regulatory benefit-risk assessmentJournal of Market Access & Health Policy · 2014
  37. Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera®) for multiple sclerosisJournal of Market Access & Health Policy · 2014
  38. Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implicationsJournal of Market Access & Health Policy · 2014
  39. Health technology assessment in middle-income countries: recommendations for a balanced assessment systemJournal of Market Access & Health Policy · 2014
  40. Novel methodology for pharmaceutical expenditure forecastJournal of Market Access & Health Policy · 2014
  41. EU pharmaceutical expenditure forecastJournal of Market Access & Health Policy · 2014
  42. Benefits of probabilistic sensitivity analysis – a review of NICE decisionsJournal of Market Access & Health Policy · 2013
  43. New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industryJournal of Market Access & Health Policy · 2013